Market Cap
$969.1M
CRVS
Corvus Pharmaceuticals, Inc.
$10.90 ▼ -0.27%
Prev close $10.93Market cap$969.1M
12-mo target$33.14 (+204.1%)
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)26 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CRVS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$545.6M
Inst. Activity
26 buys / 10 sells
Insider Activity
$333.7K buy / $0.00 sell
Insider Net $
$333.7K
SEC Reports
6
Press Releases
3
Price chart 30d -25.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 fda
Aug 21, 2026 SEC Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals initiated its Phase 1b clinical trial of soquelitinib for the treatment of pa
A strong institutional cluster formed in CRVS during 2026-Q2, with 15 buyers accumulating $24.8M in holdings (net +$14.6
INST-CLUSTER — Impact 6/10
Director Ian T. Clark resigned from the board of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years
8-K — Impact 2/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
4,474,091 shares ($66.8M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC MORGAN STANLEY — TRIM
1,344,736 shares ($20.1M)
An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Street, Fidelity, and W
INST-CLUSTER — Impact 3/10
Jun 11, 2026 Insider
Thompson Peter A. was granted 15,000 shares
Director
Jun 11, 2026 Insider
Grais Linda was granted 15,000 shares
Director
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | INITIATE | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Price targets
Where 7 covering analysts think CRVS trades over the next 12 months.
$33.14 +204.1% upside Strong Buy
Current$10.90 Low$27.00 Median$32.00 High$42.00 7 analysts
$27.00$42.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 4.3/10.Plus 3 press releases.
BULLISHINST-CLUSTER6/10
A strong institutional cluster formed in CRVS during 2026-Q2, with 15 buyers accumulating $24.8M in
Aug 21, 2026
NEUTRAL8-K2/10
Director Ian T. Clark resigned from the board of Corvus Pharmaceuticals, effective July 22, 2026, af
Jul 22, 2026
NEUTRALINST-CLUSTER3/10
An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Str
Jun 11, 2026
BULLISH8-K7/10
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID
May 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
fda
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals initiated its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
Sep 17, 2026
short_volume
Short Volume: CRVS — 86.2% short (0.6M / 0.7M)
Short: 567,152 | Exempt: 0 | TRF Vol: 657,905 | Short Ratio: 86.2% | Off-exchange volume (dark pool + OTC)
Aug 7, 2026
short_volume
Short Volume: CRVS — 66.6% short (0.3M / 0.5M)
Short: 342,350 | Exempt: 192 | TRF Vol: 513,832 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Aug 6, 2026
earnings
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track
Aug 6, 2026
earnings_calendar
CRVS Q2 2026 Earnings Scheduled — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.20 | $-0.22–$-0.18 | -70.8% | +0.0% | 0↑ 3↓ | $0.0B | 4 |
| Next Q | $-0.23 | $-0.25–$-0.18 | -51.7% | +0.0% | 0↑ 3↓ | $0.0B | 4 |
| Current FY | $-0.78 | $-0.81–$-0.71 | -44.7% | +0.0% | 0↑ 3↓ | $0.0B | 4 |
| Next FY | $-1.07 | $-1.28–$-0.83 | -37.3% | +0.0% | 0↑ 3↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.205 | — |
| 7d ago | $-0.205 | — |
| 30d ago | $-0.205 | — |
| 60d ago | $-0.188 | -0.017 |
| 90d ago | $-0.190 | -0.015 |
Institutional ownership
Which big funds own CRVS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $545.6M total value (36,525,368 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 26 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,138,811 | $106.7M | 19.5% | — |
| STATE STREET CORP | 4,474,091 | $66.8M | 12.3% | ADD +25.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,292,710 | $49.2M | 9.0% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 2,731,632 | $40.8M | 7.5% | DOUBLED +636.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,853,659 | $27.7M | 5.1% | — |
| GOLDMAN SACHS GROUP INC | 1,576,352 | $23.6M | 4.3% | — |
| Hood River Capital Management LLC | 1,571,805 | $23.5M | 4.3% | NEW |
| MORGAN STANLEY | 1,344,736 | $20.1M | 3.7% | TRIM -46.2% |
| MILLENNIUM MANAGEMENT LLC | 1,047,985 | $15.7M | 2.9% | ADD +25.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 814,750 | $12.2M | 2.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 3,565,992 | 4,474,091 | +25.5% | $66.8M |
| MORGAN STANLEY | TRIM | 2,498,825 | 1,344,736 | -46.2% | $20.1M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 237,004 | 757,798 | +219.7% | $11.3M |
| UBS Group AG | ADD | 289,114 | 396,116 | +37.0% | $5.9M |
| BARCLAYS PLC | ADD | 243,776 | 315,749 | +29.5% | $4.7M |
| Jump Financial, LLC | DOUBLED | 147,850 | 313,400 | +112.0% | $4.7M |
| Brevan Howard Capital Management LP | ADD | 167,971 | 250,291 | +49.0% | $3.7M |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 128,352 | 220,761 | +72.0% | $3.3M |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 83,907 | 217,750 | +159.5% | $3.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 38,636 | 190,641 | +393.4% | $2.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 22 transactions. Net $333.7K — $333.7K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Thompson Peter A. | Director | AWARD | 15,000 | — | — |
| Jun 11, 2026 | Grais Linda | Director | AWARD | 15,000 | — | — |
| Jun 11, 2026 | CLARK IAN T | Director | AWARD | 15,000 | — | — |
| Jun 11, 2026 | Moore David Scott | Director | BUY | 21,700 | $11.53 | $250.2K |
| Jun 11, 2026 | Moore David Scott | Director | AWARD | 15,000 | — | — |
| Jun 11, 2026 | van den Broek Richard | Director | AWARD | 15,000 | — | — |
| May 18, 2026 | MILLER RICHARD A MD | President and CEO | BUY | 5,000 | $12.05 | $60.3K |
| May 18, 2026 | MILLER RICHARD A MD | President and CEO | BUY | 1,932 | $12.01 | $23.2K |
| Apr 23, 2026 | Chan Andrew C. | Director | AWARD | 30,000 | — | — |
| Jan 28, 2026 | Thompson Peter A. | Director | EXERCISE | 30,000 | $15.00 | $450.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CRVS.
Shares short
17,180,341
Settlement Sep 15, 2026
Change vs prior
-9.7%
Semi-monthly cycle
Days to cover
18.2
At avg daily volume
Of shares outstanding
≈20.4%
Estimate — not % of float
All CRVS filing & press-release reports (9)
- INST-CLUSTER reportAug 21, 2026
- 8-K reportJul 22, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportMar 12, 2026
- PRESS-RELEASE reportMar 5, 2026